Forest Laboratories, Inc. announced today that Daliresp(TM) (roflumilast) will be available in pharmacies throughout the United States by mid-June.
The U.S. Food and Drug Administration (FDA) recently approved Daliresp as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Daliresp is the first and only selective phosphodiesterase-4 (PDE4) inhibitor approved and is an oral tablet taken once daily.
